These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 12381211)

  • 1. Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?
    Drife J
    Drug Saf; 2002; 25(13):893-902. PubMed ID: 12381211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraception and venous thromboembolism. A New Zealand perspective.
    Roke C
    Drug Saf; 1997 Feb; 16(2):79-87. PubMed ID: 9067120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Contraceptive agents and risk of thrombosis].
    Maurer-Major E; Keller PJ
    Praxis (Bern 1994); 1997 Oct; 86(40):1543-8. PubMed ID: 9417570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and mechanisms of cardiovascular events in users of oral contraceptives.
    Meade TW
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1646-52. PubMed ID: 3287935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the October 1995 pill scare in Grampian.
    Flett G; Gurney E; McKessock L; Reid J
    Br J Fam Plann; 1998 Apr; 24(1):18-20. PubMed ID: 9719702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies.
    Rekers H; Norpoth T; Michaels MA
    Eur J Contracept Reprod Health Care; 1996; 1(1):21-30. PubMed ID: 9678134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?
    Han L; Jensen JT
    Obstet Gynecol Clin North Am; 2015 Dec; 42(4):683-98. PubMed ID: 26598309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the British warning on contraceptive use in the General Medical Service in Ireland.
    Williams D; Kelly A; Carvalho M; Feely J
    Ir Med J; 1998 Dec; 91(6):202-3. PubMed ID: 10069128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes.
    Dragoman M; Curtis KM; Gaffield ME
    Contraception; 2016 Sep; 94(3):280-7. PubMed ID: 26272309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update.
    Reid R;
    J Obstet Gynaecol Can; 2010 Dec; 32(12):1192-1197. PubMed ID: 21176332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Selected aspects of oral contraception side effects].
    Wolski H
    Ginekol Pol; 2014 Dec; 85(12):944-9. PubMed ID: 25669065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of hormonal contraceptives-related venous thromboembolism.
    Hugon-Rodin J; Gompel A; Plu-Bureau G
    Eur J Endocrinol; 2014 Dec; 171(6):R221-30. PubMed ID: 25012200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism and oral contraceptives: current status and clinical implications.
    Burkman RT
    Treat Endocrinol; 2002; 1(3):143-7. PubMed ID: 15799206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal contraceptives and venous thromboembolism: an epidemiological update.
    Plu-Bureau G; Maitrot-Mantelet L; Hugon-Rodin J; Canonico M
    Best Pract Res Clin Endocrinol Metab; 2013 Feb; 27(1):25-34. PubMed ID: 23384743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis.
    Farris M; Bastianelli C; Rosato E; Brosens I; Benagiano G
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1129-1144. PubMed ID: 28712325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives and venous thromboembolic disease: the effect of the oestrogen dose.
    Melis GB; Fruzzetti F; Ricci C; Carmassi F; Fioretti P
    Maturitas; 1988; Suppl 1():131-9. PubMed ID: 3237106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic risks of oral contraceptives.
    Rott H
    Curr Opin Obstet Gynecol; 2012 Aug; 24(4):235-40. PubMed ID: 22729096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology.
    Gourdy P; Bachelot A; Catteau-Jonard S; Chabbert-Buffet N; Christin-Maître S; Conard J; Fredenrich A; Gompel A; Lamiche-Lorenzini F; Moreau C; Plu-Bureau G; Vambergue A; Vergès B; Kerlan V
    Ann Endocrinol (Paris); 2012 Nov; 73(5):469-87. PubMed ID: 23078975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral contraceptives.
    Maclennan AH
    Curr Ther (Seaforth); 1987 Dec; 28(12):113-22. PubMed ID: 12317413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.